{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Carcinoma", "query": { "condition": "Metastatic Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3759, "total_pages": 376, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T14:41:01.880Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04459273", "title": "Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Hepatocellular Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Pleural Neoplasm", "Malignant Skin Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Thymus Neoplasm", "Neuroendocrine Neoplasm", "Thyroid Gland Carcinoma", "Urothelial Carcinoma", "Cancer of Unknown Primary Site" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-08-27", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459273" }, { "nct_id": "NCT02187302", "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Standard of Care (Investigator Choice)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2014-07", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 38, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187302" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT03535727", "title": "A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma", "Pancreatic Neoplasms", "Neoplasm, Glandular", "Neoplasms", "Neoplasms Pancreatic", "Digestive System Neoplasm", "Endocrine Gland Neoplasms", "Digestive System Disease", "Pancreatic Diseases", "Endocrine System Diseases" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 48, "start_date": "2018-06-21", "completion_date": "2022-10-03", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535727" }, { "nct_id": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Salivary Gland Carcinoma", "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary", "Stage III Major Salivary Gland Carcinoma", "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Major Salivary Gland Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-10-08", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538510" }, { "nct_id": "NCT04703920", "title": "Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Castration-resistant Prostate Cancer", "Metastatic Ovarian Carcinoma", "Metastic or Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-03-04", "completion_date": "2025-01-02", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703920" }, { "nct_id": "NCT03324373", "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Partial or Radical Cytoreductive Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Yousef Zakharia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-03-20", "completion_date": "2024-08-28", "has_results": false, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03324373" }, { "nct_id": "NCT03064854", "title": "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PDR001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-05-24", "completion_date": "2021-07-28", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064854" }, { "nct_id": "NCT07043972", "title": "Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-07-09", "completion_date": "2031-01-01", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07043972" }, { "nct_id": "NCT03007979", "title": "Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Malignant Tumor of Breast" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Optional research biopsy", "type": "PROCEDURE" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Research blood draw", "type": "PROCEDURE" }, { "name": "Circulating tumor cell blood draw", "type": "PROCEDURE" }, { "name": "Tumor biopsy (optional)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 55, "start_date": "2017-06-15", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-07-22T14:41:01.880Z", "location_count": 2, "location_summary": "St Louis, Missouri • Lincoln, Nebraska", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03007979" } ] }